Physician profile
Anthony Adekunle
NPI 1659044204
$1,163.19
in general payments reported to CMS, 2019-2025
13 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.29 · 2022: $221 · 2023: $313 · 2024: $280 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $253.97 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $176.21 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $159.56 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Abbvie INC. | $158.12 | 2022-2025 | |
| Lundbeck LLC | $132.79 | 2022-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $82.21 | 2023 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $52.30 | 2022 | |
| Vanda Pharmaceuticals INC. | $40.06 | 2024 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $35.05 | 2023-2024 | Invega |
| E.R. Squibb & Sons, L.L.C. | $25.17 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $17.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.54 | 2022 | |
| Indivior INC. | $14.90 | 2024 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Adekunle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.